NorthStar Secures Ra-226 Supply with QSA Global

QSA Global Inc., a supplier of specialized radioactive source manufacturing and medical radiochemical services, and NorthStar Medical Radioisotopes, LLC, a radiopharmaceutical company, have entered a multi-year strategic services agreement designed to solidify the supply chain for radium-226 (Ra-226) targets, the starting material for Actinium-225 (Ac-225) production.

The partnership combines QSA Global’s experience in high-activity source handling, industrial regulatory compliance, and logistics with NorthStar’s unique approach to commercial-scale radiopharmaceutical production. It features a multi-year purification campaign where QSA Global will process legacy Ra-226 on behalf of NorthStar, transforming the material into high-purity precursors that will directly feed continuous target capsule manufacturing. Following irradiation and processing by NorthStar to produce n.c.a. Ac-225, the recovered radium will be returned to QSA Global for recycling into new targets—establishing a highly efficient, closed-loop supply chain.

“This multi-year agreement with QSA Global strengthens our supply chain with a reliable, high-quality supply of Ra-226 targets critical to our n.c.a. Ac-225 production capabilities,” said Dr. Frank Scholz, President & CEO of NorthStar. “By ensuring consistent access to these vital starting materials, we can confidently meet growing demand within the industry.”

“By managing the complex, highly regulated lifecycle of radium-226, QSA Global enables partners like NorthStar to focus their resources entirely on commercial Actinium-225 production,” said Joe Lapinskas, Innovation Director at QSA Global, Inc. “We are proud to leverage our decades of high-activity radioactive materials expertise to help secure this critical supply chain and support NorthStar’s mission of delivering life-saving TATs to patients.”